Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Breakthrough, Fast-Track Pathways Match Their Hype Of Reduced Development Times - JAMA

Executive Summary

Although study was meant to be critical of expedited pathways, it showed that drugs with at least one of the designations experience lower clinical development times.

Advertisement

Related Content

JAMA Study Continues Wave Of Accelerated Approval Criticism Amid Expansion Of Pathway
NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate
Safety Events For Accelerated Approval Drugs Highlighted As Expansion Looms

Topics

Advertisement
UsernamePublicRestriction

Register

PS122076

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel